Genmab — April 2021

Rondo

Bulder

Look at the share. It's E L again

E_L

just had another link, but maybe this is best,
via https://meetinglibrary.asco.org/results/amivantamab;page=0?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D , ticked the year for 2021

E_L

2 for epcoritamab - Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. and - Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Bulder

It seems there are 2 epco abs https://meetinglibrary.asco.org/results/epcoritamab?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D&page=1

E_L

i think those 2 will be the 2 most important ones?

E_L

or could be, depends on data offcourse

E_L

Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

E_L

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

E_L

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

Bulder

I assume that only the first epco abs will contain data. The second one looks more like a presenting abs.

E_L

makes sense

E_L

1 Tiso - Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).

Bulder

The new guy from Vejle is primary author on the firste epco-abs. Will be interesting how new dara are.

E_L

13x Dara; i would think the 2 most interesting are on Auriga and Cassiopeia 'part 2' ?

Bulder

Hope we'll get the full expansion cohorte.

Bulder

That should provide us with data enough to judge on the future of epco.

E_L

so that's the abstract that will determine how our summer will be

E_L

A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.

Bulder

strange that we don't hear anything from the Cepheus study. It had primary completion earlier this month.